Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease
Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease
复制标题
DOI：
10.1001/archneur.60.9.1218
复制
发表时间：
2003-09-01
影响因子：
--
通讯作者：
del Ser, T
中科院分区：
文献类型：
--
作者：
Gómez-Tortosa, E;Gonzalo, I;del Ser, T
背景资料：大多数患有路易体痴呆（DLB）的患者表现出仅弥漫性斑块的病理学，具有罕见的新皮质神经纤维缠结（NFT），这与阿尔茨海默病（AD）中广泛的皮质神经原纤维-tau蛋白参与相反。另一个病理学差异是AD脑中的神经炎性斑块和NFT周围的星形胶质细胞和小胶质细胞炎症反应，包括白细胞介素（IL）的释放，其在DLB中不存在或低得多。我们分析了反映AD和DLB之间病理差异的脑脊液（CSF）标志物。目的：测定CSF中tau蛋白、β-淀粉样蛋白、IL-1 β和IL-6的浓度，作为区分AD和DLB的潜在诊断线索。我们测量了33名可能患有AD但无帕金森综合征的患者的CSF样本中的总tau、β-淀粉样蛋白（1-42）、IL-1 β和IL-6水平，结果：AD组tau蛋白水平显著高于DLB组和对照组（P
Background: Most patients with dementia with Lewy bodies (DLB) exhibit diffuse plaque-only pathology with rare neocortical neurofibrillary tangles (NFTs), as opposed to the widespread cortical neurofibrillary-tau involvement in Alzheimer disease (AD). Another pathological difference is the astrocytic and microglial inflammatory responses, including release of interleukins (ILs), around the neuritic plaques and NFTs in AD brains that are absent or much lower in DLB. We analyzed cerebrospinal fluid (CSF) markers that reflect the pathological differences between AD and DLB.Objective: To determine CSF concentrations of tau, beta-amyloid, IL-1beta, and IL-6 as potential diagnostic clues to distinguish between AD and DLB.Methods: We measured total tau, beta-amyloid(1-42), IL-1beta, and IL-6 levels in CSF samples of 33 patients with probable AD without parkinsonism, 25 patients with all the core features of DLB, and 46 age-matched controls.Results: Patients with AD had significantly higher levels of tau protein than patients with DLB and controls (P